To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

October 09, 2018

Today's Rundown

Featured Story

Novartis cozies up to Silicon Valley with new lab

Novartis is set to open innovation labs around the world to connect with tech companies. The labs, the first of which has opened in San Francisco, will serve as a bridge between companies developing R&D-enhancing technologies and the broader Novartis business.

Top Stories

Affimed tumbles as FDA puts brakes on T cell engager

The FDA has slapped a clinical hold on two phase 1 trials of Affimed’s lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.

Rgenix bags $40M to advance cancer drugs, including GSK castoff

New York biotech Rgenix has raised $40 million in series C financing to carry out early and midstage trials of an immunotherapy for solid tumors and a cancer metabolism inhibitor for gastrointestinal cancers.

Rare disease startup Therachon to absorb GLyPharma and its SBS candidate

Fresh off a $60 million raise, the Novo Holdings-backed startup Therachon announced plans to buy GLyPharma Therapeutic and make the leap to becoming a multi-asset rare disease company.

Sinntaxis bags option on ex-AstraZeneca mGluR5 antagonist

Sinntaxis has secured an option on an ex-AstraZeneca drug. AstraZeneca dropped mGluR5 antagonist AZD2066 after getting a look at midphase data, but Sinntaxis thinks it can rehabilitate the molecule as a treatment for stroke patients.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Unlocking New Business Value in Life Sciences with Digital Technology

Collaborate in a digital world to improve patient outcomes.

[Whitepaper] Is Your In-House Strategy Ready For The Uncertainties Of Biologic Drug Development?

Read this whitepaper to learn more about two main areas where a drug developer can face significant obstacles during biologics development.

[Research] Linguistic and Cultural Considerations When Implementing a Global BYOD Study

Examine the linguistic and cultural considerations of global eCOA and BYOD.

[eBook] Healthcare and Life Sciences - Data Value Chain

Download our new eBook to learn how Healthcare and Life Sciences organizations are taking advantage of solutions from AWS and the AWS Partner Network to obtain value from critical data.

[Infographic] Flexible. Scalable. Proactive.

Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries.

[Case Study] FSP Insourcing – Relationship Growth Built on Results, Trust

Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries.

[POCKET GUIDE] 3 Steps To Supercharge Your Literature Search

Go from Search to Full-Text Scientific Papers in a Single Click!

[Whitepaper] How to Re-Design your Regulatory Capabilities

A top 20 pharma and growing biotech re-engineer regulatory processes.

[Whitepaper] The Future of Pharmacovigilance: Leveraging Technology and Automation

Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be!

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

[eLearning] BIOAVAILABILITY 101

Develop a basic understanding of principles and concepts of bioavailability of oral drugs.

Events

.